Cadre Holdings Inc. announced that its subsidiary Med‑Eng, LLC has been awarded a five‑year Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the U.S. Department of War. The contract, valued at a maximum of $50 million, will provide Med‑Eng with a steady stream of government orders for its Blast Exposure Monitoring (BEMO) program, which includes sensor hardware and software that records blast overpressure exposures during training operations.
Med‑Eng has been a pioneer in body‑worn blast sensors since 2006, and the BEMO program builds on that legacy by offering a comprehensive monitoring solution that helps the military assess and mitigate blast risks. The award reinforces Med‑Eng’s dominant position in the bomb‑suit and blast‑sensor market and expands its footprint in the defense sector.
Cadre’s recent earnings demonstrate a healthy trajectory: net sales rose 42% year‑over‑year to $155.9 million in Q3 2025, and adjusted EBITDA reached $29.8 million, a margin of 19.1%. The company’s gross profit margin expanded to 42.7% from 36.6% in the prior year, reflecting pricing power and efficient cost management. The new contract represents roughly 8% of Cadre’s trailing‑12‑month revenue of $619 million, underscoring its significance to the company’s top‑line growth.
Management highlighted the strategic importance of the award. President Brad Williams said, “We are honored to be selected as the provider of a sensor technology solution that will significantly enhance the ability of the U.S. military to monitor, track, and evaluate blast overpressure exposure events warfighters receive in training.” CEO Warren Kanders added, “The contract is a testament to Med‑Eng’s ability to develop best‑in‑class systems that support operational requirements and keep users safe.”
Cadre’s broader strategy includes recent acquisitions that strengthen its safety‑equipment portfolio. The company agreed to acquire TYR Tactical for $175 million, expected to close in 2026, and the Engineering Division from Carr’s Group plc for £75 million, bolstering its nuclear safety vertical. Full‑year 2025 guidance remains robust, with net sales projected between $624 million and $630 million and adjusted EBITDA between $112 million and $116 million, reflecting confidence in continued demand and the impact of these strategic moves.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.